Concepedia

Heike Richly

HR

Statistics

Publications

35

Citations

2.7K

H-Index

24

Active since

2002

Affiliations

University of Duisburg-Essen(Current)

Essen University Hospital

Bayer (Germany)

West German Heart and Vascular Center Essen

Bayer (United States)

Heike Richly is an author at University of Duisburg-Essen specializing in medicine, oncology, and pharmacology.

Publications per year

2002–2024

35

Publications

35

Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors

Dirk Strumberg, Heike Richly, Ralf A. Hilger et al. · Journal of Clinical Oncology · 2004 · 871 citations · Full text

, , +16

Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study

Dirk Strumberg, M. E. Scheulen, Beate Schultheis et al. · British Journal of Cancer · 2012 · 254 citations · Full text

, , +16

Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study

Martin Schüler, Byoung Chul Cho, Cyrus Sayehli et al. · The Lancet Oncology · 2019 · 174 citations

, , +11

A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer

Uğur Şahin, Martin Schüler, Heike Richly et al. · European Journal of Cancer · 2018 · 164 citations · Full text

, , +17

Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors

Heike Richly, Bernhard F. Henning, P. Kupsch et al. · Annals of Oncology · 2006 · 142 citations · Full text

, , +11

1–5 of 35